NPI-2358

· Nereus Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NPI-2358, covering 2011-01-10 to 2011-08-16. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

See pricing